Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Lu-177 Psma I&t
2. G5b860b0g1
3. Lutetium (177lu) Zadavotide Guraxetan [inn]
4. 2447131-70-4
5. Unii-g5b860b0g1
6. Lutetium Lu 177 Psma I&t
7. Lutetate(5-)-177lu, (n-((4r)-4-(carboxy-.kappa.o)-4-(4,7,10-tris((carboxy-.kappa.o)methyl)-1,4,7,10-tetraazacyclododec-1-yl-.kappa.n1,.kappa.n4,.kappa.n7,.kappa.n10)-1-oxobutyl)-3-iodo-d-tyrosyl-d-phenylalanyl-n6-(8-(((5s)-5-carboxy-5-(((((1s)-1,3-dicarboxypropyl)amino)carbonyl)amino)pentyl)amino)-1,8-dioxooctyl)-d-lysinato(8-))-, Hydrogen (1:5)
| Molecular Weight | 1672.3 g/mol |
|---|---|
| Molecular Formula | C63H89ILuN11O23 |
| Hydrogen Bond Donor Count | 13 |
| Hydrogen Bond Acceptor Count | 27 |
| Rotatable Bond Count | 37 |
| Exact Mass | 1671.46151 g/mol |
| Monoisotopic Mass | 1671.46151 g/mol |
| Topological Polar Surface Area | 541 Ų |
| Heavy Atom Count | 99 |
| Formal Charge | 0 |
| Complexity | 2550 |
| Isotope Atom Count | 1 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 7 |
Drugs in Development
Details:
The acquisition enhances Curium’s manufacturing of Lutetium-177 to meet the growing demand for isotope around the world. Curium’s Lu-177 (Lutetium-177 PSMA-I&T) is being evaluated for Prostate Cancer.
Lead Product(s): Lutetium-177 PSMA-I&T,Lutetium (177Lu) Zadavotide Guraxetan,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Radiolabeled Compound
Sponsor: CURIUM US LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 28, 2025
Lead Product(s) : Lutetium-177 PSMA-I&T,Lutetium (177Lu) Zadavotide Guraxetan,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : CURIUM US LLC
Deal Size : Undisclosed
Deal Type : Acquisition
Curium Completes Monrol Acquisition To Expand Lutetium-177 Capacity
Details : The acquisition enhances Curium’s manufacturing of Lutetium-177 to meet the growing demand for isotope around the world. Curium’s Lu-177 (Lutetium-177 PSMA-I&T) is being evaluated for Prostate Cancer.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Undisclosed
March 28, 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
33
PharmaCompass offers a list of Lutetium (177Lu) Zadavotide Guraxetan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Lutetium (177Lu) Zadavotide Guraxetan manufacturer or Lutetium (177Lu) Zadavotide Guraxetan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lutetium (177Lu) Zadavotide Guraxetan manufacturer or Lutetium (177Lu) Zadavotide Guraxetan supplier.
A Lutetium (177Lu) Zadavotide Guraxetan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lutetium (177Lu) Zadavotide Guraxetan, including repackagers and relabelers. The FDA regulates Lutetium (177Lu) Zadavotide Guraxetan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lutetium (177Lu) Zadavotide Guraxetan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lutetium (177Lu) Zadavotide Guraxetan supplier is an individual or a company that provides Lutetium (177Lu) Zadavotide Guraxetan active pharmaceutical ingredient (API) or Lutetium (177Lu) Zadavotide Guraxetan finished formulations upon request. The Lutetium (177Lu) Zadavotide Guraxetan suppliers may include Lutetium (177Lu) Zadavotide Guraxetan API manufacturers, exporters, distributors and traders.
Lutetium (177Lu) Zadavotide Guraxetan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lutetium (177Lu) Zadavotide Guraxetan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Lutetium (177Lu) Zadavotide Guraxetan GMP manufacturer or Lutetium (177Lu) Zadavotide Guraxetan GMP API supplier for your needs.
A Lutetium (177Lu) Zadavotide Guraxetan CoA (Certificate of Analysis) is a formal document that attests to Lutetium (177Lu) Zadavotide Guraxetan's compliance with Lutetium (177Lu) Zadavotide Guraxetan specifications and serves as a tool for batch-level quality control.
Lutetium (177Lu) Zadavotide Guraxetan CoA mostly includes findings from lab analyses of a specific batch. For each Lutetium (177Lu) Zadavotide Guraxetan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lutetium (177Lu) Zadavotide Guraxetan may be tested according to a variety of international standards, such as European Pharmacopoeia (Lutetium (177Lu) Zadavotide Guraxetan EP), Lutetium (177Lu) Zadavotide Guraxetan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lutetium (177Lu) Zadavotide Guraxetan USP).
